Results 1 to 10 of about 14,325 (202)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension [PDF]

open access: goldLife
Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone’s efficacy in treating chronic heart failure.
Akira Sezai   +5 more
doaj   +4 more sources

Real-world practice patterns of eplerenone use for central serous chorioretinopathy [PDF]

open access: goldInternational Journal of Retina and Vitreous, 2023
Purpose To report eplerenone use by retina specialists worldwide for central serous chorioretinopathy (CSCR). Methods A self-reporting questionnaire was distributed to retina specialists worldwide to gather clinicians’ perspectives on CSCR cases treated,
Ramesh Venkatesh   +10 more
doaj   +2 more sources

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy [PDF]

open access: goldScientific Reports, 2022
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto   +10 more
doaj   +2 more sources

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

open access: diamondЛечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova   +3 more
doaj   +2 more sources

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms [PDF]

open access: hybrid, 2014
Aim In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II ...
Dawn Lee   +9 more
openalex   +6 more sources

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

open access: goldVascular Health and Risk Management, 2018
Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department ...
Fernet M   +5 more
doaj   +3 more sources

Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy [PDF]

open access: yesScientific Reports
Preeclampsia is a severe pregnancy complication associated with substantial injury to systemic vasculature, major organs, and the feto-placental unit, with an approximate mortality rate of 76,000 pregnant women and 500,000 babies each year.
Natalie K. Binder   +7 more
doaj   +2 more sources

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension [PDF]

open access: gold, 2018
BACKGROUND: Aldosterone is a mineralocorticoid hormone critically involved in arterial blood pressure regulation. Although pharmacological aldosterone antagonism reduces mortality and morbidity among patients with severe left-sided heart failure, the ...
Mario Boehm   +13 more
openalex   +4 more sources

Home - About - Disclaimer - Privacy